Yüklüyor......
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
Whereas target-specific drugs are available for treating ERBB2-overexpressing and hormone receptor-positive breast cancers, no tailored therapy exists for hormone receptor- and ERBB2-negative (“triple-negative”) mammary carcinomas. Triple-negative tumors account for 15% of all breast cancers and fre...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
National Academy of Sciences
2008
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2579381/ https://ncbi.nlm.nih.gov/pubmed/18971340 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.0806092105 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|